Clinical trial
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian…
NCT00041041 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00041041 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 60 |
| Start date | Jun 1, 2002 |
| Primary completion | Jan 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: